NASDAQ:AFMD
Affimed N.V. Stock News
$5.35
-0.140 (-2.55%)
At Close: Apr 30, 2024
Affimed: Updates To Thesis, Time To Gain Exposure To Innate Immuno-Oncology
12:58pm, Wednesday, 01'st Jul 2020
Shares have risen by 145% since my initial recommendation and by 65% since my October update. In ROTY's model account, our full-size, maximum-weighted position
Will Affimed Continue to Surge Higher?
03:03pm, Tuesday, 30'th Jun 2020
As of late, it has definitely been a great time to be an investor of Affimed
Implied Volatility Surging for Affimed (AFMD) Stock Options
12:43pm, Monday, 29'th Jun 2020
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
Hedge Funds Have Never Been This Bullish On Affimed NV (AFMD)
09:57pm, Sunday, 28'th Jun 2020
In this article we will check out the progression of hedge fund sentiment towards Affimed NV (NASDAQ:AFMD) and determine whether it is a good investment right now. We at Insider Monkey like to examine
Affimed N.V. (NASDAQ:AFMD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
10:02am, Thursday, 25'th Jun 2020
Affimed N.V. (NASDAQ:AFMD) defied analyst predictions to release its first-quarter results, which were ahead of market...
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) * ADC Therapeutics SA (NYSE: ADCT) * Adver
Affimed: Q1 Earnings Insights
11:04am, Tuesday, 23'rd Jun 2020
Shares of Affimed (NASDAQ:AFMD) decreased 3.0% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share fell 500.00% year over year to ($0.12), which beat the e
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2020 Results - Earnings Call Transcript
10:50am, Tuesday, 23'rd Jun 2020
Affimed N.V. (NASDAQ:AFMD) Q1 2020 Earnings Conference Call June 23, 2020 08:30 AM ET Company Participants Alexander Fudukidis - Head, Investor Relations Adi Ho
Affimed Reports First Quarter 2020 Financial Results and Operational Progress
10:30am, Tuesday, 23'rd Jun 2020
AFM24: Affimed successfully completed the first dose cohort of its first-in-human phase 1/2A Study; Cohort 2 is open for patient recruitment Data on Affimed’s.
Data Presented at AACR Virtual Annual Meeting II demonstrate that Affimed’s ROCK® platform has the ability to produce diverse Innate Cell Engagers for a multitude of.
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:34pm, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Affim
AFM24, designed to activate innate immunity to broadly target EGFR-expressing solid tumors regardless of mutational status, has the potential to improve efficacy and safety.
Affimed (AFMD) Catches Eye: Stock Jumps 7.2%
01:47pm, Tuesday, 16'th Jun 2020
Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Affimed N.V. (AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release first quarter 2020 results on
Edited Transcript of AFMD earnings conference call or presentation 28-Apr-20 12:30pm GMT
06:23am, Friday, 12'th Jun 2020
Full Year 2019 Affimed NV Earnings Call
